NeuroSense advances PrimeC, a dual-mechanism oral treatment combining ciprofloxacin and celecoxib, toward Health Canada approval based on Phase 2b data showing a 14.9-month median survival benefit and achievement of the prespecified TDP-43 biomarker endpoint. The drug targets multiple pathological pathways in ALS through anti-inflammatory and antimicrobial mechanisms.
Key Points
- 14.9-month median survival benefit versus natural history controls
- Achieved prespecified TDP-43 biomarker reduction endpoint
- Multi-pathway mechanism addresses inflammation, protein aggregation, and neuroinflammation
Longevity Analysis
ALS represents a system-wide degenerative process affecting motor neurons, energy production capacity, and cellular defense mechanisms. PrimeC's multi-target approach—addressing both protein aggregation and neuroinflammatory cascades—reflects a shift toward therapies that engage multiple points of failure rather than single-pathway interventions. The survival benefit magnitude and biomarker confirmation suggest the drug may preserve motor neuron function and slow the deterioration of structural and nervous system integrity, which are critical determinants of functional longevity in ALS populations.
Original published by Longevity.Technology.